The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them

As of today, only two antiangiogenic monoclonal antibodies plus epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) combinations are FDA and EMA-approved and are recommended by American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocco, Danilo, Della Gravara, Luigi, Palazzolo, Giovanni, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771735/
https://www.ncbi.nlm.nih.gov/pubmed/36627900
http://dx.doi.org/10.20517/cdr.2022.77

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771735/
https://www.ncbi.nlm.nih.gov/pubmed/36627900
http://dx.doi.org/10.20517/cdr.2022.77

Ejemplares similares